<DOC>
	<DOCNO>NCT02387164</DOCNO>
	<brief_summary>The purpose study evaluate immune-tolerance Alum-formulated GAD ( Diamyd ) , combination high dose Vitamin D3 , may delay stop autoimmune process lead clinical type 1 diabetes non-diabetic child ongoing beta-cell autoimmunity indicate positive islet autoantibody .</brief_summary>
	<brief_title>Prevention Trial : Immune-tolerance With Alum-GAD ( Diamyd ) Vitamin D3 Children With Multiple Islet Autoantibodies</brief_title>
	<detailed_description>The primary objective study evaluate immune-tolerance Alum-formulated GAD ( Diamyd ) , combine high dose Vitamin D3 , may delay stop autoimmune process lead clinical type 1 diabetes ( diagnose accord American Diabetes Association criterion ) non-diabetic 4-17.99 year old child ongoing beta-cell autoimmunity indicate positive islet autoantibody . The secondary objective demonstrate treatment Diamyd safe child risk type 1 diabetes . The child follow 5 year study . Primary endpoint proportion subject diagnose type 1 diabetes treatment arm . Secondary endpoint 1 ) safety , 2 ) change metabolic status normal impair glucose metabolism group child normal glucose metabolism baseline screening .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Children 417.99 year age positive autoantibody glutamate decarboxylase ( GADA ) least one additional type 1 diabetes associate autoantibody ( insulinoma associate protein 2 ( IA2A ) , Zinktransporter 8 ( ZnT8R/Q/WA ) insulin ( IAA ) ) . Written inform consent child child legal representative ( ) . 1 . Ongoing treatment immunosuppressant therapy . 2 . Diabetes . 3 . Treatment oral inject antidiabetic medication 4 . Significantly abnormal hematology result screen . 5 . Clinically significant history acute reaction vaccine drug 6 . Treatment vaccine within one month prior first dose study drug plan treatment vaccine three month last injection study drug . 7 . A history epilepsy , serious head trauma cerebrovascular accident , Clinical feature continuous motor unit activity proximal muscle 8 . Participation Clinical trial new chemical entity within previous 3 month . 9 . History hypercalcemia . 10 . Unwilling abstain medication Vitamin D study period . 11 . Significant illness within 2 week prior first dose . 12 . Known Human Immuno Deficiency Virus infection hepatitis . 13 . Presence associate serious disease condition . 14 . Diabetesprotective Human Leucocyte Antigen ( HLA ) DQ6 . 15 . Females lactate pregnant . 16 . Males female willing use adequate contraception , sexually active , 1 year last Diamyd administration .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Islet autoantibody</keyword>
	<keyword>glutamate decarboxylase autoantibody ( GADA )</keyword>
	<keyword>Immune tolerance</keyword>
	<keyword>Prediabetes</keyword>
	<keyword>Glucose tolerance</keyword>
	<keyword>glutamate decarboxylase</keyword>
	<keyword>Prevention</keyword>
	<keyword>Children</keyword>
</DOC>